Viewing Study NCT06009003

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:10 PM
Ignite Modification Date: 2026-01-02 @ 7:54 AM
Study NCT ID: NCT06009003
Status: TEMPORARILY_NOT_AVAILABLE
Last Update Posted: 2024-08-06
First Post: 2023-08-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Individual Patient Esmethadone (REL-1017) Expanded Access Program
Sponsor: Relmada Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Major Depressive Disorder View
None Depression View
Keywords:

Keywords

Keyword Brief Keyword Text View
None REL-1017 View
None esmethadone View
None Relmada View
None antidepressant View
None NMDA receptor antagonist View
None Depression View